Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons

NACompletedINTERVENTIONAL
Enrollment

1,368

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
TuberculosisLatent Tuberculosis InfectionHIV Infections
Interventions
DRUG

isoniazid

A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)

DRUG

Placebo

A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)

Trial Locations (1)

Unknown

Ubuntu Clinic,Site B Khayelitsha, Cape Town

All Listed Sponsors
collaborator

Medecins Sans Frontieres, Netherlands

OTHER

collaborator

Imperial College London

OTHER

collaborator

Johns Hopkins University

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

University of Cape Town

OTHER

NCT00463086 - Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons | Biotech Hunter | Biotech Hunter